Text Size

Prospective Liver Study

This study is currently recruiting participants.
Verified October 2012 by Emory University
Sponsor:
Information provided by (Responsible Party):
Hyun Kevin Kim, Emory University
ClinicalTrials.gov Identifier:
NCT01539993
First received: February 15, 2012
Last updated: October 25, 2012
Last verified: October 2012
History of Changes
  Purpose

This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.


Condition
Liver Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prospective Analysis of Liver Cancer Treatment and Interventions

Resource links provided by NLM:

MedlinePlus related topics: Cancer Liver Cancer
U.S. FDA Resources

Further study details as provided by Emory University:

Primary Outcome Measures:
  • Assess efficacy of percutaneous and transarterial treatments for liver cancer. [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    QOL questionnaire will be collected during follow up visit.


Secondary Outcome Measures:
  • long term follow up [ Time Frame: 3 months, 6 months 1year ] [ Designated as safety issue: No ]
    Patients will be administered QOL during 3 months, 6 months and 1 year follow up.


Estimated Enrollment: 1000
Study Start Date: November 2008
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients 18 yrs and older with a diagnosis of Hepatocellular carcinoma and elegible for percutaneous liver treatments

Criteria

Inclusion Criteria:

  • Patients diagnosed with Hepatocellular carcinoma and referred for percutaneous liver treatment.

Exclusion Criteria:

  • Severe liver disfunction
  • Active uncontrolled infection
  • Significant underlying medical of physical illness
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01539993

Contacts
Contact: Maria V Rivas (404)712-7962 mrivas2@emory.edu
Contact: Hyun S Kim, MD 1888-946-7447 hkim286@emory.edu

Locations
United States, Georgia
Emory University Recruiting
Atlanta, Georgia, United States, 30322
Principal Investigator: Hyun S Kim, MD FSIR            
Sponsors and Collaborators
Emory University
Investigators
Principal Investigator: Kevin S Kim, MD Emory University
  More Information

No publications provided

Responsible Party: Hyun Kevin Kim, MD FSIR, Director of Interventional Radiology and Image-Guided Medicine., Emory University
ClinicalTrials.gov Identifier: NCT01539993     History of Changes
Other Study ID Numbers: 00014768
Study First Received: February 15, 2012
Last Updated: October 25, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Emory University:
Hepatocellular carcinoma
Liver metastases
Cholangiocarcinoma
Percutaneous treatments
 RFA
TACE
DEB

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
 Neoplasms
Digestive System Diseases
Liver Diseases

ClinicalTrials.gov processed this record on May 21, 2013